Phase II study of 5?-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma | Zendy

P. Alberto | Zendy; Marcel Rozencweig | Zendy; M. Clavel | Zendy; P Siegenthaler | Zendy; Franco Cavalli | Zendy; S. Gundersen | Zendy; U. Bruntsch | Zendy; J. Renard | Zendy; Herbert M. Pinedo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase II study of 5?-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma

Author(s) -

P. Alberto,

Marcel Rozencweig,

M. Clavel,

P Siegenthaler,

Franco Cavalli,

S. Gundersen,

U. Bruntsch,

J. Renard,

Herbert M. Pinedo

Publication year - 1986

Publication title -

cancer chemotherapy and pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.112

H-Index - 111

eISSN - 1432-0843

pISSN - 0344-5704

DOI - 10.1007/bf00255292

Subject(s) - nausea , leukopenia , vomiting , medicine , melanoma , chemotherapy , stomatitis , toxicity , ataxia , gastroenterology , oncology , cancer research , psychiatry

Forty-two patients with malignant melanoma were treated with doxifluridine, 4000 mg/m2 daily X 5, repeated every 3 weeks. The daily dose was reduced to 3000 mg/m2 in patients who had experienced severe myelosuppression with prior chemotherapy. A total of 35 patients were evaluable for response, and 25 of these received two or more courses. Two responses were observed. Toxicity mainly took the form of nausea, vomiting, stomatitis, dizziness, ataxia, and fatigue. Mild leukopenia was frequent (43%). Nadir counts less than 1.5 X 10(9)/l leukocytes or 50 X 10(9)/l platelets were seen in 7% and 2% of the courses respectively. Doxifluridine has no useful activity against malignant melanoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research